Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
ID: 349497Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $475K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/349497

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting proposals for the "Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)" grant, aimed at fostering transformative discoveries in cancer biology through the application of nanotechnology. This initiative, led by the National Cancer Institute (NCI), seeks projects that address significant challenges in oncology by conducting mechanistic studies on nanomaterial interactions with biological systems, although clinical applications are not within the scope of this funding opportunity. The program emphasizes the importance of advancing cancer treatment and diagnostics through innovative research, with a funding ceiling of $475,000 per year for a maximum duration of five years. Interested applicants must submit their proposals by May 4, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-23-246.html for more details.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-246-Full-Announcement.html
    PAR-23-246.html
    The National Institutes of Health (NIH) is soliciting proposals through the Notice of Funding Opportunity (NOFO) titled "Innovative Research in Cancer Nanotechnology (IRCN)." This initiative, spearheaded by the National Cancer Institute (NCI), aims to foster transformative discoveries in cancer biology using nanotechnology. Proposed projects must focus on understanding and addressing key challenges in oncology through fundamental mechanistic studies, but clinical applications are outside its scope. Key elements include application deadlines from October 3, 2023, to the final expiration on May 5, 2026, with anticipated budgets of $475,000 annually and a maximum project duration of five years. Eligible applicants range from educational institutions to for-profit organizations. The initiative promotes multi-disciplinary collaboration, encouraging ways to enhance nanoparticle delivery methods, improve diagnostics, and understand tumor microenvironments. Applications will be rigorously evaluated on significance, investigator qualifications, innovation, and overall approach, ensuring that only groundbreaking, scientifically robust projects receive funding. Compliance with registration processes and data management sharing is mandatory for potential applicants. This initiative underscores the NIH's commitment to advancing cancer treatment and diagnostic innovation through nanotechnology.
    Similar Opportunities
    Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), aimed at advancing cancer treatment through innovative nanotechnology-based diagnostics and therapeutics. This initiative supports advanced pre-clinical research focused on developing nanoparticle and nano-device interventions that enhance the effectiveness of cancer treatments, particularly in combination therapy, immunotherapy, and imaging. The program emphasizes multidisciplinary collaboration and requires proposals to outline clear milestones for project advancement, with a maximum budget of $475,000 in direct costs annually over a project period of up to four years. Interested applicants must submit their proposals by November 17, 2024, and can find additional information and application guidelines at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research," aimed at advancing innovative research in biomimetic tissue-engineered technologies for cancer. This initiative seeks to support collaborative, multidisciplinary projects that integrate regenerative medicine, tissue engineering, and cancer biology to develop advanced in vitro and ex vivo models that accurately mimic human cancer pathophysiology. The funding opportunity is crucial for enhancing cancer research methodologies and understanding disease mechanisms, with a maximum budget of $400,000 per year and a project duration of up to five years. Interested applicants must submit their proposals electronically via Grants.gov by May 8, 2025, and can reach out to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the National Cancer Institute (NCI) for investigator-initiated early phase clinical trials focused on cancer treatment and diagnosis, specifically under the R01 Research Project Grant mechanism (PAR-24-085). This initiative invites research proposals for Phase 0, I, and II clinical trials that align with the missions of various NCI programs, while explicitly excluding Phase III trials. The program aims to advance cancer research by assessing novel therapeutic and diagnostic interventions, improving imaging technologies, and exploring treatment combinations, with applications encouraged from a diverse range of eligible organizations, including educational institutions and non-profits. Interested applicants should note that the submission deadlines begin on January 5, 2024, with the opportunity closing on January 8, 2027. For further details, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/pa-files/PAR-24-085.html.
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NCI Small Grants Program for Cancer Research (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the NCI Small Grants Program for Cancer Research (R03), aimed at supporting short-term cancer research projects that require limited resources. This funding opportunity encourages diverse research efforts, including pilot studies, secondary data analyses, and the development of research methodologies, with a maximum budget of $50,000 per year for projects lasting up to two years. The program is designed to address significant knowledge gaps in cancer research and is open to a wide range of applicants, including public, private, and foreign entities. Interested parties should note that the application period opens on January 24, 2025, with a submission deadline of February 24, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NCI Outstanding Investigator Award (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NCI Outstanding Investigator Award (R35), aimed at providing long-term support for exceptional cancer research projects. This grant opportunity is designed for accomplished investigators with a proven track record in cancer research, allowing them to pursue innovative and high-risk projects that could lead to significant advancements in the field. The award offers up to $600,000 in direct costs per year for a maximum duration of seven years, with applications due by November 7, 2024. Interested applicants can find more information and contact details at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html.
    NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced the NCI Small Grants Program for Cancer Research (R03) for the years 2023 to 2025. This funding opportunity is designed to support small-scale research projects on cancer that can be completed within a two-year timeframe and with limited resources, including pilot studies, secondary data analyses, and the development of research methodologies or technologies. Grants of up to $50,000 per year are available to a wide range of eligible applicants, including higher education institutions, nonprofits, and various community organizations. Interested parties should submit their applications electronically via Grants.gov, with the first submission deadline having been January 22, 2023, and subsequent deadlines continuing through 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R01 Clinical Trial Not Allowed), aimed at advancing research on the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between bacteria, archaebacteria, bacteriophages, and tumors, focusing on their potential to enhance cancer imaging, therapeutics, and diagnostics, particularly for solid tumors. The program encourages multidisciplinary collaborations and aims to address current limitations in cancer therapies, with a significant emphasis on improving treatment outcomes in low-resource settings. Interested applicants can find more information and submit their proposals by May 7, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem," aimed at supporting exploratory research projects in cancer communication. This initiative focuses on three key areas: developing new cancer communication surveillance strategies, creating rapid intervention methods, and establishing multilevel communication models to enhance cancer prevention and control efforts. The NIH emphasizes the importance of utilizing contemporary methodologies, such as social media analysis and artificial intelligence, to address misinformation and improve health literacy in cancer care. Eligible applicants can receive funding of up to $275,000 for a maximum duration of two years, with applications due by September 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the detailed announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-165.html.